Related Experiment Video
Updated: Sep 9, 2025

Conversion of Human Induced Pluripotent Stem Cells iPSCs into Functional Spinal and Cranial Motor Neurons Using PiggyBac Vectors
Published on: May 1, 2019
Toggling of NKG2A expression drives functional specialization of iPSC-derived CAR NK cells
Minoru Kanaya1, Camille Philippon1, Herman Netskar1,2
1Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Abstract:
Induced pluripotent stem cell (iPSC)-derived natural killer (iNK) cells offer a promising platform for off-the-shelf immunotherapy against hematological malignancies. NK cell function is dynamically regulated through education driven by inhibitory receptors, including CD94/NKG2A and killer cell immunoglobulin-like receptors (KIR). However, the acquisition of inhibitory receptors in iNK cells and their role during differentiation and education remains poorly defined. In this study, we monitored receptor repertoires, transcriptional states, and functional responses in a range of genetically engineered iNK cell lines. Transcriptional reference mapping placed iNK cells close to cytokine-activated NKG2A+ CD56dim peripheral blood (PB) NK cells. Despite their early differentiation stage, iNK cells displayed a well-developed cytotoxic effector program, which was also reflected in high protein expression of Eomes, granzyme B, and activating receptors DNAM-1 and NKG2D. Acquisition of NKG2A by iNK cells was associated with a more differentiated transcriptional state and superior functional responses against a broad range of targets, including those expressing low to moderate levels of HLA-E, suggesting attenuated inhibitory signaling through NKG2A in iNKs. CRISPR knockout of β2-microglobulin (B2M) in iNK cells revealed that the functional potency of NKG2A+ iNK cells was independent of educating interactions with HLA-E in cis or trans. Finally, CRISPR-mediated ablation of NKG2A led to a spontaneous compensatory surface expression of CD94/NKG2C heterodimers, associated with enhanced IFN-γ production and cytotoxic activity against target cells with forced high expression of single-chain β2m-HLA-E-peptide trimers. Our results indicate an education-independent functional maturation of iNK cells, characterized by potent effector programs coupled with a favorable early-stage transcriptional profile.
Insights
Induced pluripotent stem cell (iPSC)-derived natural killer (iNK) cells show potent anti-cancer activity. These iNK cells mature independently of inhibitory receptor education, demonstrating strong effector functions for immunotherapy.
Area of Science:
- Immunology
- Cell Biology
- Cancer Research
Background:
- Induced pluripotent stem cell (iPSC)-derived natural killer (iNK) cells are a promising immunotherapy for hematological malignancies.
- NK cell function is regulated by inhibitory receptors like CD94/NKG2A and KIR, but their role in iNK cell differentiation and education is unclear.
Purpose of the Study:
- To investigate the acquisition and function of inhibitory receptors during iNK cell differentiation.
- To determine the role of education by HLA-E in iNK cell maturation and function.
Main Methods:
- Monitoring receptor repertoires, transcriptional states, and functional responses in engineered iNK cell lines.
- Transcriptional reference mapping to compare iNK cells with peripheral blood NK cells.
- CRISPR-Cas9 gene editing to knock out B2M and ablate NKG2A in iNK cells.
Main Results:
- iNK cells exhibit a well-developed cytotoxic effector program and express high levels of Eomes, granzyme B, DNAM-1, and NKG2D.
- NKG2A acquisition correlates with a more differentiated state and enhanced function, with attenuated inhibitory signaling.
- NKG2A+ iNK cell potency is independent of HLA-E education; NKG2A ablation leads to compensatory NKG2C expression and enhanced cytotoxicity.
Conclusions:
- iNK cells undergo education-independent functional maturation with potent effector programs.
- iNK cells possess a favorable early-stage transcriptional profile for immunotherapy.
- These findings support the potential of iNK cells as an off-the-shelf immunotherapy for hematological cancers.

